Clinical Trials Directory

Trials / Completed

CompletedNCT00115921

Evaluation of Home-Based Management of Fever in Urban Ugandan Children

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
540 (planned)
Sponsor
London School of Hygiene and Tropical Medicine · Academic / Other
Sex
All
Age
1 Year – 5 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to see if providing effective antimalarial treatment at home for parents/guardians to treat their children for malaria will lead to an improved health outcome compared to conventional healthcare.

Detailed description

Population: Representative sample of Ugandan children aged 1 to 5 years from 400 households (approximately 540 children). Clinical Site: The study will be conducted in the Mulago III parish community of Kampala, Uganda. Study Duration: 13 months Study Intervention: \*Pilot period: After enrollment, households will participate in a one month pilot period to test the household pictorial diaries. At the end of the pilot period, households will be randomized to participation in the home-based management of fever (HBMF) arm or standard care arm for the remainder of the study (12 months). \*HBMF arm: Households randomized to the HBMF group will be provided with pre-packaged coartemether to keep at home. Primary caregivers will be instructed to treat children participating in the study empirically with coartemether at home when the child develops fever. Study personnel will distribute drugs and educate the caregivers about administration of drugs, recognition of danger signs of fever/malaria, and when to seek additional care. \*Standard care: Households randomized to the standard care arm will be asked to continue their current behaviour and to manage fever in their children as they would normally. Measurements: Household diaries and monthly visits. Primary caregivers will be asked to keep a diary regarding the health of study participants for the duration of the study (13 months). Information on illnesses, treatments given, visits to health care facilities, and health care expenditures will be collected. Study personnel will visit the households monthly to collect completed diaries. At each visit, questionnaires will be administered to gather additional data on the health of the participants and treatment seeking behaviour. Clinical and laboratory evaluations: Temperature, height, weight, mid-upper arm circumference, spleen size, haemoglobin, and thick blood smear will be assessed at enrollment, and at the beginning and end of the intervention period. Study Objectives: 1. To measure the impact of home-based management of fever with coartemether on malaria-related morbidity compared to the current standard of care in the community. 2\. To measure the impact of home-based management of fever with coartemether on economic measures compared to the current standard of care in the community. Primary outcome: Treatment incidence density (treatments per time at risk) for each treatment arm Secondary clinical outcomes: 1) mean days of fever; 2) incidence of febrile episodes; 3) mean haemoglobin at study end; 4) change in mean haemoglobin; 5) prevalence of splenomegaly; 6) prevalence of parasitaemia; 7) incidence of visits to health care facilities, and hospitalizations; 8) mortality rate; 9) anthropometric measurements; 10) proportion of "appropriate" treatments; 11) proportion of delayed treatments; 12) treatment incidence density of treatments given at \>50% and at full dose Economic outcomes: 1) household cost/febrile episode; 2) household costs for treatment of febrile episode/month; 3) provider cost/child for delivery of HBMF; 4) estimated provider facility cost/patient for uncomplicated fever, and for severe disease; 5) total net cost/child/year; 6) net cost/additional child appropriately treated; 7) net cost/day of fever averted

Conditions

Interventions

TypeNameDescription
BEHAVIORALProvision of antimalarial treatment at home

Timeline

Start date
2005-07-01
Completion
2007-04-01
First posted
2005-06-27
Last updated
2017-01-12

Source: ClinicalTrials.gov record NCT00115921. Inclusion in this directory is not an endorsement.